Literature DB >> 15629270

Use of standard criteria for assessment of cancer vaccines.

Nicholas P Restifo1, Steven A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15629270      PMCID： PMC1484507          DOI： 10.1016/S1470-2045(04)01693-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Part I: Vaccines for solid tumours.

Authors:  Simone Mocellin; Susanna Mandruzzato; Vincenzo Bronte; Mario Lise; Donato Nitti
Journal:  Lancet Oncol       Date:  2004-11       Impact factor: 41.316

3.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

4.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

5.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

6.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Authors:  Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas C Palmer; Yutaka Tagaya; Steven A Rosenberg; Thomas A Waldmann; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

7.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307
  7 in total
  4 in total

Review 1.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 3.  CD8+ T-cell memory in tumor immunology and immunotherapy.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

4.  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.

Authors:  C M Britten; C Gouttefangeas; M J P Welters; G Pawelec; S Koch; C Ottensmeier; A Mander; S Walter; A Paschen; J Müller-Berghaus; I Haas; A Mackensen; T Køllgaard; P thor Straten; M Schmitt; K Giannopoulos; R Maier; H Veelken; C Bertinetti; A Konur; C Huber; S Stevanović; T Wölfel; S H van der Burg
Journal:  Cancer Immunol Immunother       Date:  2007-08-25       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.